IP Library Granted Patent US 8,927,508
Granted Patent B2
US 8,927,508 · App. 12/271,603 · Granted Jan 6, 2015

Antibody production elicited by a DNA vaccine delivered by electroporation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,927,508
App. No.
12/271,603
Granted
Jan 6, 2015
Kind
B2
Abstract

There are provided methods of generating antibodies in a mammal against recombinant antigens using DNA plasmids capable of expressing said antigens in cells of said mammal, comprising: injecting into tissue of said mammal a DNA plasmid comprising an encoding sequence operably linked to a promoter, electroporating said tissue with an electroporation device capable of delivering an electrical pulse effective to electroporate cells of said tissue to allow entry of said DNA plasmid and expression of said antigen, and allowing said mammal to respond to said expressed antigen in order to generate antibodies to said antigen. Furthermore, there are provided methods of isolating antibodies specific against desired antigens wherein said antibodies are generated in a mammal using DNA plasmids capable of expressing said antigens.

Claims (51)

1. A method of generating antibodies in a mammal against recombinant antigens, wherein said antigen is influenza HA, influenza NA, or influenza M2e-NP, using DNA plasmids capable of expressing said antigens in cells of said mammal, comprising:

injecting into tissue of said mammal a DNA plasmid consisting essentially of an encoding sequence operably linked to a promoter, wherein the encoding sequence encodes a protein consisting of the antigen,

electroporating said tissue with an electroporation device capable of delivering an electrical pulse effective to electroporate cells of said tissue to allow entry of said DNA plasmid and expression of said antigen, and

allowing said mammal to respond to said expressed antigen in order to generate antibodies to said antigen

wherein the electroporating step comprises delivering a current of 0.5 Amp.

2. The method of claim 1 , wherein said antibodies are neutralizing antibodies.

3. The method of claim 1 , wherein said antibodies are isotypes IgG1 or IgG2a.

4. The method of claim 1 , said electroporating step comprising electroporating said tissue with a constant-current electroporation device.

5. The method of claim 1 , wherein said current is a constant current throughout pulse duration.

6. The method of claim 1 , wherein said electroporating step is undertaken from about 1 sec to about 20 sec after said injecting step.

7. The method of claim 1 , wherein said electorporating step is undertaken from about 1 sec to about 10 sec after said injecting step.

8. The method of claim 1 , wherein said electorporating step is undertaken from about 1 sec to about 5 sec after said injecting step.

9. The method of claim 1 , wherein said electorporating step is undertaken about 4 sec after said injecting step.

10. The method of claim 1 , said electroporating step comprising delivering more than one electrical pulse.

11. The method of claim 1 , said electroporating step comprising delivering three electrical pulses.

12. The method of claim 10 , said electroporating step comprising pausing about 0.1 sec to about 5 sec between electrical pulses.

13. The method of claim 10 , said electroporating step comprising pausing about 1 sec between electrical pulses.

14. The method of claim 1 , wherein said DNA plasmid is injected in said injecting step in concentrations of greater than 1 mg/ml.

15. The method of claim 14 , wherein said concentrations of DNA plasmid is greater than 2 mg/ml.

16. The method of claim 14 , wherein said concentrations of DNA plasmid is greater than 4 mg/ml.

17. The method of claim 1 , wherein said method is repeated in a subsequent day.

18. The method of claim 1 , further comprising delivering a protein boost of said antigen to said mammal at a subsequent day.

19. The method of claim 1 , wherein the injecting step is injecting into intramuscular or intradermic tissue see claim 40 .

20. The method of claim 1 , wherein the injecting step further comprises injecting an adjuvant.

21. A method of isolating antibodies specific against desired antigens, wherein said antigen is influenza HA, influenza NA, or influenza M2e-NP and wherein said antibodies are generated in a mammal using DNA plasmids capable of expressing said antigens in cells of said mammal, comprising:

injecting into tissue of said mammal a DNA plasmid consisting essentially of an encoding sequence operably linked to a promoter, wherein the encoding sequence encodes a protein consisting of the antigen,

electroporating said tissue with an electroporation device capable of delivering an electrical pulse effective to electroporate cells of said tissue to allow entry of said DNA plasmid and expression of said antigen,

allowing said mammal to respond to said expressed antigen in order to generate antibodies to said antigen,

collecting serum from said mammal, and

extracting the antibodies from the serum

wherein the electroporating step comprises delivering a current of 0.5 Amp.

22. The method of claim 21 , further comprising purifying the extracted antibodies.

23. The method of claim 21 , wherein said antibodies are neutralizing antibodies.

24. The method of claim 21 , wherein said antibodies are isotypes IgG1 or IgG2a.

25. The method of claim 21 , said electroporating step comprising electroporating said tissue with a constant-current electroporation device.

26. The method of claim 21 , wherein said current is a constant current throughout pulse duration.

27. The method of claim 21 , wherein said electroporating step is undertaken from about 1 sec to about 20 sec after said injecting step.

28. The method of claim 21 , wherein said electroporating step is undertaken from about 1 sec to about 10 sec after said injecting step.

29. The method of claim 21 , wherein said electroporating step is undertaken from about 1 sec to about 5 sec after said injecting step.

30. The method of claim 21 , wherein said electroporating step is undertaken about 4 sec after said injecting step.

31. The method of claim 21 , said electroporating step comprising delivering more than one electrical pulse.

32. The method of claim 21 , said electroporating step comprising delivering three electrical pulses.

33. The method of claim 30 , said electroporating step comprising pausing about 0.1 sec to about 5 sec between electrical pulses.

34. The method of claim 30 , said electroporating step comprising pausing about 1 sec between electrical pulses.

35. The method of claim 21 , wherein said DNA plasmid is injected in said injecting step in concentrations of greater than 1 mg/ml.

36. The method of claim 35 , wherein said concentrations of DNA plasmid is greater than 2 mg/ml.

37. The method of claim 35 , wherein said concentrations of DNA plasmid is greater than 4 mg/ml.

38. The method of claim 21 , wherein said method is repeated in a subsequent day.

39. The method of claim 21 , further comprising delivering a protein boost of said antigen to said mammal at a subsequent day.

40. The method of claim 21 , wherein the injecting step is either injecting into intramuscular or intradermic tissue.

41. The method of claim 21 , wherein the injecting step further comprises injecting an adjuvant.

Assignments (3)
MERGER Recorded Feb 2, 2021
From: VGX PHARMACEUTICALS, LLC
To: INOVIO PHARMACEUTICALS, INC.
Reel/Frame 055114/0843 →
MERGER AND CHANGE OF NAME Recorded Dec 21, 2020
From: VGX PHARMACEUTICALS, INC.; INOVIO ACQUISITION, LLC
To: VGX PHARMACEUTICALS, LLC
Reel/Frame 054704/0830 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2009
From: DRAGHIA-AKLI, RUXANDRA; KHAN, AMIR S.
To: VGX PHARMACEUTICALS, INC.
Reel/Frame 022360/0516 →